Abstract
The prevalence of calcific aortic stenosis (AS) and of cardiac amyloidosis (CA) increases with age, and their association is not uncommon in the elderly. The identification of CA is particularly challenging in patients with AS because these 2 conditions share several features. It is estimated that ≤15% of the AS population and ≤30% of the subset with low-flow, low-gradient pattern may have CA. In patients with AS, CA is associated with increased risk of heart failure, mortality, and treatment futility with aortic valve replacement. In case of suspicion of CA, it is thus crucial to confirm the diagnosis to guide therapeutic management of AS and eventually implement recently developed pharmacological treatment dedicated to transthyretin amyloidosis. Given the high surgical risk of patients with AS and concomitant CA, transcatheter aortic valve replacement may be preferred to surgery in these patients.
[Display omitted]
•CA may be present in ≤15% of patients with AS.•Clinical and imaging “red flags” for CA should be systematically searched in patients with AS.•Transcatheter rather than surgical AVR may be preferred in patients with CA.•Recently developed pharmacological treatment for transthyretin CA should be instituted as soon as diagnosis is confirmed.